MMP9 and myeloid sarcoma: MMP-9/TIMP-1 ratios are significantly altered in MS lesions [32] and changes in MMP-9 levels are known to contribute to the disruption of the blood-brain barrier and degradation of extra-cellular matrix [33], activities which are regulated by its endogenous inhibitor TIMP-1.